Medicare

Chemistry of Type-2 Diabetes Tablets

August 6, 2025
admin

Disclaimer

The information provided here is intended solely for educational and awareness purposes. It is based on publicly available pharmaceutical and biomedical sources regarding the chemistry, pharmacokinetics, and therapeutic rationale of metformin hydrochloride and related drug formulations.

  • This content does not constitute medical advice, diagnosis, or treatment.
  • Always consult a qualified healthcare professional or licensed pharmacist before starting, stopping, or modifying any medication or therapy.
  • Drug formulations, dosing regimens, and side effect profiles may vary between individuals based on health status, age, comorbidities, and other medications.
  • Product names mentioned (e.g., Glycomet-GP, Gemer) are trademarks of their respective manufacturers and are referenced for informational purposes only.
  • The chemical and pharmacological data summarized here is not a substitute for regulatory documents, such as drug monographs, prescribing information, or scientific publications approved by authorities like the DCGI, FDA, or EMA.

Use responsibly. Stay informed. Consult experts.

Dr E. Ramanathan PhD in Chemistry

Comparative Drug Chemistry Table: Glycomet-GP 1 vs. Gemer 1

FeatureGlycomet-GP 1Gemer 1
ManufacturerUSV LimitedSun Pharmaceutical Industries Ltd
Drug ClassAntidiabetic combinationAntidiabetic combination
CompositionGlimepiride 1 mg + Metformin 500 mgGlimepiride 1 mg + Metformin 500 mg
Glimepiride ClassSulfonylureaSulfonylurea
Metformin ClassBiguanideBiguanide
Mechanism – GlimepirideStimulates insulin secretion from β-cellsStimulates insulin secretion from β-cells
Mechanism – MetforminInhibits hepatic glucose production & increases insulin sensitivitySame
Glimepiride MW~490.6 g/mol~490.6 g/mol
Metformin MW~165.6 g/mol (as HCl)~165.6 g/mol (as HCl)
Key Functional GroupsSulfonylurea (Glimepiride), Biguanide (Metformin)Same
PharmacokineticsOral, hepatic metabolism (Glimepiride); renal excretion (Metformin)Same
Risk of HypoglycemiaPresent (due to Glimepiride)Present (due to Glimepiride)
UsageType 2 DiabetesType 2 Diabetes
Brand DifferenceUSV brand with specific excipients and bioequivalenceSun Pharma brand with similar core ingredients

Both drugs are pharmaceutically equivalent and typically interchangeable unless patient-specific excipient tolerance or availability is a concern.

References

Here are authoritative references for the drug chemistry and product information of Glycomet-GP 1 and Gemer 1:

1. Glimepiride

2. Metformin Hydrochloride

3. Product References

4. Pharmacology Textbook

  • Goodman & Gilman’s The Pharmacological Basis of Therapeutics – 13th Edition
    (Chapter on antidiabetic drugs)

How is the prolonged release of Metformin hydrochloride achieved?

Prolonged (or sustained) release of Metformin hydrochloride is achieved using the following pharmaceutical formulation techniques:

1. Matrix Systems

  • Hydrophilic Matrix (e.g., HPMC – hydroxypropyl methylcellulose):
    • Upon ingestion, the tablet forms a gel layer that slows drug diffusion.
    • As the outer layer hydrates and erodes, metformin is gradually released.
    • Most common method in marketed SR (sustained-release) tablets.

2. Osmotic Pump Systems

  • Example: Glucophage XR (extended-release)
    • Uses an osmotic push-pull mechanism:
      • Drug core is surrounded by a semipermeable membrane.
      • Water enters → pushes metformin through a laser-drilled orifice at controlled rate.

3. Coated Pellets or Beads (Multiparticulate Systems)

  • Metformin granules or pellets are coated with pH-dependent or time-controlled polymers like:
    • Ethylcellulose, Eudragit RS/RL, etc.
  • These coatings control drug release based on diffusion or erosion.

4. Ion Exchange Resins

  • Drug is complexed with resins that release metformin slowly in response to ion exchange in the GI tract.

5. Lipid-Based Systems

  • Wax matrix tablets (e.g., carnauba wax, glyceryl behenate) delay release via erosion or diffusion.

Goals Achieved

  • Once-daily dosing
  • Reduced GI side effects
  • Steady plasma concentration
  • Improved patient compliance

Why is prolonged release of Metformin Hydrochloride needed ?

Prolonged release of Metformin Hydrochloride needed for the following clinical and pharmacokinetic reasons:

1. Reduces Gastrointestinal (GI) Side Effects

  • Immediate-release (IR) metformin can cause nausea, diarrhea, bloating, and abdominal discomfort due to high local concentration in the gut.
  • Prolonged-release (PR) formulations release the drug slowly in the GI tract, minimizing mucosal irritation.

2. Improves Patient Compliance

  • PR formulations are typically once-daily, unlike IR versions which require 2–3 daily doses.
  • Simpler regimens = better adherence in chronic therapy like Type 2 diabetes.

3. Provides Stable Blood Glucose Control

  • PR forms produce more stable plasma drug levels with fewer peaks and troughs.
  • Reduces the risk of subtherapeutic effects or mild hypoglycemia.

4. Extends Duration of Action

  • Metformin IR has a half-life of ~6 hours and needs multiple doses/day.
  • PR formulations extend release over 10–24 hours, maintaining therapeutic levels longer.

5. Enhances Absorption at Preferred GI Sites

  • Metformin is mainly absorbed in the duodenum and jejunum.
  • PR forms can be engineered to release the drug in these proximal regions, optimizing absorption.

6. Reduces Inter- and Intra-patient Variability

  • Smoother release profiles lead to more predictable pharmacokinetics, especially important in long-term glycemic control.

Summary Table

BenefitImmediate ReleaseProlonged Release
Dosing frequency2–3 times dailyOnce daily
GI side effectsHigherLower
Peak–trough plasma fluctuationSignificantMinimal
Patient complianceModerateImproved
Plasma level stabilityLess stableMore stable

Prolonged release metformin (e.g., Glucophage XR) has thus become a preferred formulation in clinical practice for better tolerability, efficacy, and compliance.

Leave a Reply

wpChatIcon